Can subsequent therapies be administered after the ZEVALIN therapeutic regimen?
In a retrospective analysis of patients with relapsed or refractory NHL who experienced disease progression after the ZEVALIN therapeutic regimen and received subsequent therapy (n = 58), it was concluded that chemotherapy or autologous stem-cell transplantation (ASCT) after prior administration of Y-90 ZEVALIN was feasible and reasonably well tolerated. Patients analyzed had indolent, transformed, aggressive, or mantle cell NHL (not all of which are included in the labeled indication for ZEVALIN).3* Clinical responses were achieved when chemotherapy (e.g., CHOP, CVP/COP, purine analogs), rituximab, interferon, radiation therapy, or ASCT was administered after the ZEVALIN therapeutic regimen. Toxicities associated with subsequent therapies included infusion-related symptoms, grade 4 neutropenia, grade 4 thrombocytopenia, neutropenic fever, complications requiring hospitalization, and toxicities requiring the use of granulocyte colony-stimulating factor or red blood cell or platelet tra
